{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:36:14Z","timestamp":1790451374240,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013678","name":"Cancer Center, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX000141"],"award-info":[{"award-number":["BX000141"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["P30AR057212"],"award-info":[{"award-number":["P30AR057212"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jid.2021.11.035","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:39:43Z","timestamp":1640000383000},"page":"1912-1922.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-8115","authenticated-orcid":false,"given":"Nabanita","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-5854","authenticated-orcid":false,"given":"Chiara R.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-8819","authenticated-orcid":false,"given":"Carol M.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7707-7987","authenticated-orcid":false,"given":"Adam","family":"Honig-Frand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-0523","authenticated-orcid":false,"given":"James R.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-9394","authenticated-orcid":false,"given":"Karoline A.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1875-9691","authenticated-orcid":false,"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-4534","authenticated-orcid":false,"given":"Richard P.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-1713","authenticated-orcid":false,"given":"Martin D.","family":"McCarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-2229","authenticated-orcid":false,"given":"Kasey L.","family":"Couts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1925","authenticated-orcid":false,"given":"Mayumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7481-737X","authenticated-orcid":false,"given":"David A.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-5753","authenticated-orcid":false,"given":"Yiqun G.","family":"Shellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.11.035_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2021.11.035_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcp.29044","article-title":"Cancer stem cells: a review from origin to therapeutic implications","volume":"235","author":"Atashzar","year":"2020","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jid.2021.11.035_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41420-020-0259-2","article-title":"Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells","volume":"6","author":"Bellini","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jid.2021.11.035_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data [published correction appears in Cancer Discov 2012;2:960]","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2021.11.035_bib5","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.2147\/OTT.S284262","article-title":"Research progress of cancer stem cells in uveal melanoma","volume":"13","author":"Chen","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jid.2021.11.035_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5311","article-title":"BH3 mimetics: weapons of cancer cell destruction","volume":"11","author":"Chonghaile","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2021.11.035_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/cancers11060846","article-title":"Targeted therapy of uveal melanoma: recent failures and new perspectives","volume":"11","author":"Croce","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.11.035_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/cells9051287","article-title":"Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer","volume":"9","author":"D\u2019Aguanno","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jid.2021.11.035_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-021-01926-6","article-title":"Hypoxia-dependent drivers of melanoma progression","volume":"40","author":"D\u2019Aguanno","year":"2021","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.11.035_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/ph14080749","article-title":"A\u00a0novel regimen for treating melanoma: MCL1 inhibitors and azacitidine","volume":"14","author":"Dart","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jid.2021.11.035_bib11","author":"Goodman"},{"key":"10.1016\/j.jid.2021.11.035_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2021.11.035_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biocel.2014.11.015","article-title":"Role of the pro-survival molecule Bfl-1 in melanoma","volume":"59","author":"Hind","year":"2015","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jid.2021.11.035_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jid.2021.11.035_bib15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1078-0432.CCR-20-2860","article-title":"Combined inhibition of G\u03b1q and MEK enhances therapeutic efficacy in uveal melanoma","volume":"27","author":"Hitchman","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.11.035_bib16","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","volume":"8","author":"Hoefsmit","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jid.2021.11.035_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archopht.120.4.466","article-title":"Immunophenotypic differences between uveal and cutaneous melanomas","volume":"120","author":"Iwamoto","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jid.2021.11.035_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.11.035_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jid.2021.11.035_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jid.2021.11.035_bib21","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1167\/iovs.11-7379","article-title":"Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and\u00a0survive chemotherapy","volume":"52","author":"Kalirai","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2021.11.035_bib22","doi-asserted-by":"crossref","first-page":"118987","DOI":"10.1016\/j.bbamcr.2021.118987","article-title":"It's time to die: BH3 mimetics in solid tumors","volume":"1868","author":"Kehr","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jid.2021.11.035_bib23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2021.11.035_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jid.2021.11.035_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jid.2021.11.035_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1541-7786.MCR-18-0574","article-title":"Effects of oncogenic G\u03b1q and G\u03b111 inhibition by FR900359 in uveal melanoma","volume":"17","author":"Lapadula","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jid.2021.11.035_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10495-021-01667-z","article-title":"The role of p53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases","volume":"26","author":"Li","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.jid.2021.11.035_bib28","first-page":"411","article-title":"Opposite roles of BAP1 in overall survival of uveal melanoma and cutaneous melanoma","volume":"9","author":"Liu-Smith","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jid.2021.11.035_bib29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2147\/OPTH.S113623","article-title":"Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012)","volume":"10","author":"Mahendraraj","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jid.2021.11.035_bib30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jid.2021.11.035_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the","volume":"103","author":"McLaughlin","year":"2005","journal-title":"U.S. Cancer"},{"key":"10.1016\/j.jid.2021.11.035_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2021.11.035_bib33","doi-asserted-by":"crossref","first-page":"84594","DOI":"10.18632\/oncotarget.13141","article-title":"Combining a GSI and BCL-2 inhibitor to overcome melanoma\u2019s resistance to current treatments","volume":"7","author":"Mukherjee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2021.11.035_bib34","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/cancers12082182","article-title":"Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma","volume":"12","author":"Mukherjee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.11.035_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-0716-1205-7_14","article-title":"Enrichment of melanoma stem-like cells via sphere assays","volume":"2265","author":"Mukherjee","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2021.11.035_bib36","doi-asserted-by":"crossref","first-page":"46801","DOI":"10.18632\/oncotarget.8695","article-title":"Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells","volume":"8","author":"Mukherjee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2021.11.035_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/jid.2014.464","article-title":"Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells","volume":"135","author":"Mukherjee","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.035_bib38","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/jid.2015.145","article-title":"Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells","volume":"135","author":"Mukherjee","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.035_bib39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/MIK665 plus navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","author":"Mukherjee","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2021.11.035_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41419-018-0932-z","article-title":"BH3 mimetics induce apoptosis independent of DRP-1 in melanoma","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2021.11.035_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/156802611794072641","article-title":"Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death","volume":"11","author":"Mustata","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jid.2021.11.035_bib42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2021.11.035_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00008390-200112000-00006","article-title":"Comparison of the ex\u00a0vivo chemosensitivity of uveal and cutaneous melanoma","volume":"11","author":"Neale","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2021.11.035_bib44","doi-asserted-by":"crossref","first-page":"e80836","DOI":"10.1371\/journal.pone.0080836","article-title":"Targeting Bcl-2\/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts","volume":"9","author":"N\u00e9mati","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.11.035_bib45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1101\/gad.296962.117","article-title":"Focus on cutaneous and uveal melanoma specificities","volume":"31","author":"Pandiani","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.jid.2021.11.035_bib46","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","article-title":"Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma [published correction appears in Clin Cancer Res 2021;27:4664]","volume":"27","author":"Paradis","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.11.035_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41419-021-03500-6","article-title":"The application of BH3 mimetics in myeloid leukemias","volume":"12","author":"Parry","year":"2021","journal-title":"Cell Death Dis"},{"issue":"Suppl. 13","key":"10.1016\/j.jid.2021.11.035_bib48","article-title":"Phase 3 randomized trial comparing tebentafusp with investigator\u2019s choice in first line metastatic uveal melanoma","volume":"81","author":"Piperno-Neumann","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2021.11.035_bib49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/pcmr.12853","article-title":"Mouse models of uveal melanoma: strengths, weaknesses, and future directions","volume":"33","author":"Richards","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2021.11.035_bib50","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1038\/s41467-019-12409-w","article-title":"Targeting melanoma\u2019s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1\/2 pathway inhibitors","volume":"10","author":"Sale","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.11.035_bib51","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/cancers11081048","article-title":"Immunotherapies for the treatment of uveal melanoma-history and future","volume":"11","author":"Schank","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.11.035_bib52","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/sj.onc.1210771","article-title":"Bfl-1\/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist","volume":"27","author":"Simmons","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.11.035_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2021.11.035_bib54","doi-asserted-by":"crossref","first-page":"360136","DOI":"10.1155\/2010\/360136","article-title":"Genetics of uveal melanoma and cutaneous melanoma: two of a kind?","volume":"2010","author":"van den Bosch","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.jid.2021.11.035_bib55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/cancers11060845","article-title":"Uveal versus cutaneous melanoma; same origin, very distinct tumor types","volume":"11","author":"van der Kooij","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.11.035_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jid.2021.11.035_bib57","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/onc.2009.45","article-title":"PUMA, a potent killer with or without p53","volume":"27","author":"Yu","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.11.035_bib58","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4155\/fmc-2020-0004","article-title":"Targeting anti-apoptotic BCL-2 family proteins for cancer treatment","volume":"12","author":"Zhang","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.jid.2021.11.035_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [published correction appears in Pharmacol Rev 2007;59:124]","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jid.2021.11.035_bib60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-0716-1205-7_14","article-title":"Enrichment of melanoma stem-like cells via sphere assays","volume":"2265","author":"Mukherjee","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2021.11.035_bib61","doi-asserted-by":"crossref","first-page":"46801","DOI":"10.18632\/oncotarget.8695","article-title":"Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells","volume":"8","author":"Mukherjee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2021.11.035_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/jid.2014.464","article-title":"Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells","volume":"135","author":"Mukherjee","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.035_bib63","doi-asserted-by":"crossref","first-page":"e24294","DOI":"10.1371\/journal.pone.0024294","article-title":"The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53","volume":"6","author":"Reuland","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.11.035_bib64","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.jid.5700211","article-title":"RhoC promotes human melanoma invasion in a PI3K\/Akt-Dependent pathway","volume":"126","author":"Ruth","year":"2006","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21026178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21026178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:49:52Z","timestamp":1762206592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21026178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0022202X21026178"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.035","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}